X4 Pharmaceuticals (XFOR) Hisse Özeti
Bir biyofarmasötik şirketi olan X4 Pharmaceuticals, Inc. bağışıklık sisteminin nadir hastalıklarının tedavisi için yeni terapötiklerin araştırılması, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
XFOR Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
X4 Pharmaceuticals, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$3.50 |
| 52 Haftanın En Yüksek Seviyesi | US$4.83 |
| 52 Haftanın En Düşük Seviyesi | US$2.80 |
| Beta | 0.39 |
| 1 Aylık Değişim | -18.41% |
| 3 Aylık Değişim | -12.50% |
| 1 Yıllık Değişim | 7.36% |
| 3 Yıllık Değişim | -89.49% |
| 5 Yıllık Değişim | -97.79% |
| Halka arzdan bu yana değişim | -99.23% |
Son Haberler & Güncellemeler
Seeking Alpha • Aug 19
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)
Summary X4 Pharmaceuticals has made progress since our March 3, 2026 BUY Rating: European approval in April, Norgine on the marketing authorization in July, and Q2 revenue of $8.8 million. The registered share count omits 30.2 million pre-funded warrants exercisable at $0.001, which X4's own income statement counts, making the company $127 million more expensive than it appears. X4 owes Hercules $77 million on July 1, 2027, while XOLREMDI sales held between $2.3 million and $2.5 million for three straight quarters, and the company issues no guidance. We believe new investors should wait for the FDA sample-size outcome. At Avalon Capital Research, we rate X4 Pharmaceuticals a HOLD. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 12
Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts
Celebrations may be in order for X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) shareholders, with the analysts delivering a...Analiz Makalesi • Aug 10
Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates
As you might know, X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) just kicked off its latest quarterly results with some very...Recent updates
Seeking Alpha • Aug 19
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)
Summary X4 Pharmaceuticals has made progress since our March 3, 2026 BUY Rating: European approval in April, Norgine on the marketing authorization in July, and Q2 revenue of $8.8 million. The registered share count omits 30.2 million pre-funded warrants exercisable at $0.001, which X4's own income statement counts, making the company $127 million more expensive than it appears. X4 owes Hercules $77 million on July 1, 2027, while XOLREMDI sales held between $2.3 million and $2.5 million for three straight quarters, and the company issues no guidance. We believe new investors should wait for the FDA sample-size outcome. At Avalon Capital Research, we rate X4 Pharmaceuticals a HOLD. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 12
Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts
Celebrations may be in order for X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) shareholders, with the analysts delivering a...Analiz Makalesi • Aug 10
Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates
As you might know, X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) just kicked off its latest quarterly results with some very...
Anlatı Güncellemesi • Jun 17
XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential
Analysts have raised their 12 month price target on X4 Pharmaceuticals stock from $10 to $12, citing a more constructive view of the company’s lead program mavorixafor and its potential in the large, underpenetrated chronic neutropenia market. What’s in the News for X4 Pharmaceuticals X4 Pharmaceuticals received European Commission marketing authorization for XOLREMDI (mavorixafor) capsules to treat patients aged 12 and older with WHIM syndrome in the European Union, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.
Anlatı Güncellemesi • Jun 03
XFOR: Chronic Neutropenia Opportunity Will Drive Future Upside Potential
Narrative Update on X4 Pharmaceuticals The consensus analyst price target for X4 Pharmaceuticals has moved to $12, with analysts pointing to the potential of lead drug mavorixafor in chronic neutropenia and WHIM syndrome as the main factor in their valuation analysis. Analyst Commentary Bullish analysts are highlighting X4 Pharmaceuticals as a focused rare disease story centered on mavorixafor, with both chronic neutropenia and WHIM syndrome at the core of their views.
Anlatı Güncellemesi • May 20
XFOR: Single Asset CXCR4 Platform Is Poised To Drive Upside
Analysts have lifted their price target on X4 Pharmaceuticals to $11.67 from $8.00, citing a stronger outlook for mavorixafor as a potential first in class oral CXCR4 antagonist in WHIM syndrome and primary chronic neutropenia. They note that the current valuation does not fully reflect its role as the company's key value driver.Anlatı Güncellemesi • May 04
XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential
Analysts have raised their price target on X4 Pharmaceuticals to $12, citing what they view as significant upside potential from mavorixafor as a key value driver for WHIM syndrome and primary chronic neutropenia, along with a current valuation that they see as not fully reflecting this opportunity. Analyst Commentary Recent Street research frames X4 Pharmaceuticals as a focused hematology company, with attention centered on mavorixafor as a potential first in class oral CXCR4 antagonist for WHIM syndrome and primary chronic neutropenia.Anlatı Güncellemesi • Apr 20
XFOR: CXCR4 Program In WHIM And Chronic Neutropenia Will Drive Future Upside
Analysts have reset their price target on X4 Pharmaceuticals to $12, citing Guggenheim's recent initiation, which highlights mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary The latest Street research frames X4 Pharmaceuticals as closely tied to the success of mavorixafor in WHIM syndrome and primary chronic neutropenia.Anlatı Güncellemesi • Apr 05
XFOR: Mavorixafor Franchise Is Expected To Drive Future Upside Potential
Narrative Update Analysts have raised their price target for X4 Pharmaceuticals to $12, citing the perceived upside in mavorixafor as a key value driver and updating fair value assumptions to $10.00, along with adjusted growth, margin, discount rate, and future P/E inputs. Analyst Commentary Recent research points to mavorixafor as the central piece of the X4 Pharmaceuticals story, with coverage initiating at a $12 price target that aligns with the view of the drug as a key value driver.Anlatı Güncellemesi • Mar 22
XFOR: WHIM And Chronic Neutropenia Program Will Drive Future Upside
Analysts have adjusted their price target on X4 Pharmaceuticals to $12, noting what they view as potential upside tied to mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary Recent commentary from bullish analysts centers on how mavorixafor could reshape the risk reward profile for X4 Pharmaceuticals, especially as the program advances in WHIM syndrome and primary chronic neutropenia.Anlatı Güncellemesi • Mar 07
XFOR: EU WHIM Decision And Chronic Neutropenia Program Will Drive Upside Potential
Analysts have reset their price target for X4 Pharmaceuticals to $13.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that they see as better aligned with the company’s current risk and earnings profile. What's in the News The European Medicines Agency's CHMP adopted a positive opinion recommending marketing authorization, under exceptional circumstances, for mavorixafor to treat WHIM syndrome in the EU (Key Developments).Anlatı Güncellemesi • Feb 21
XFOR: Higher Fair Value Will Reflect Stronger Outlook Despite Margin Headwinds
Analysts have lifted their fair value estimate for X4 Pharmaceuticals from $4.00 to $5.00 per share, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the new price target. Valuation Changes Fair Value was raised from $4.00 to $5.00 per share, an increase of 25% in the modelled estimate.Anlatı Güncellemesi • Feb 06
XFOR: Fair Value View Will Balance Dilution Concerns And Execution Milestones
Analysts have lifted their price target on X4 Pharmaceuticals to $4.00 per share from $4.00, citing updated assumptions around revenue growth, discount rate, profit margin, and future P/E that are now reflected in their models. Valuation Changes Fair Value: Maintained at $4.00 per share, with no change from the prior estimate.Anlatı Güncellemesi • Jan 23
XFOR: Future Outlook Weighs October Financing Dilution Against Execution And Earnings Milestones
Narrative Update Analysts have trimmed their 12 month price target on X4 Pharmaceuticals to US$7.50 from US$9.00, mainly reflecting updated financing assumptions after the recent earnings report and the October capital raise. Analyst Commentary Bearish analysts are using the latest earnings report and the October capital raise to reset expectations on X4 Pharmaceuticals, with the 12 month price target update to US$7.50 at the center of their view.Anlatı Güncellemesi • Jan 09
XFOR: Future Outlook Balances October Financing Dilution With Execution And Earnings Milestones
Analysts have trimmed their 12 month price target for X4 Pharmaceuticals to US$7.50 from US$9.00, citing updated financing assumptions following the October capital raise as well as recent earnings and corporate updates. Analyst Commentary Bearish analysts are framing the lower US$7.50 12 month price target as a reset that reflects updated expectations after recent earnings and the October capital raise.Analiz Makalesi • Dec 24
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon
With a median price-to-sales (or "P/S") ratio of close to 12.4x in the Biotechs industry in the United States, you...Anlatı Güncellemesi • Dec 22
XFOR Future Outlook Weighs Financing Dilution Against Long Term Commercial Upside
Analysts have trimmed their price target on X4 Pharmaceuticals by $1.50 to $7.50, citing updated models that factor in revised financing assumptions following the company’s recent earnings report and October capital raise. Analyst Commentary Bearish analysts have pointed to the latest target cut as evidence that X4 Pharmaceuticals faces a more challenging path to value creation than previously modeled, with revised financing assumptions weighing on upside potential.Anlatı Güncellemesi • Dec 07
XFOR: Recent Financing Will Support Key Phase 3 Progress And Upside Potential
Analysts have modestly trimmed their fair value estimate for X4 Pharmaceuticals, cutting the price target from $9.00 to $7.50, as updated models incorporate revised financing assumptions following the company's recent capital raise. Analyst Commentary Analyst updates following the latest earnings report and corporate update emphasize that the lower price target is primarily a function of revised financing assumptions rather than a fundamental shift in the long term outlook for X4 Pharmaceuticals.Anlatı Güncellemesi • Nov 23
XFOR: Leadership Overhaul And Fresh Capital Will Drive Pipeline Progress
Analysts have revised their price target for X4 Pharmaceuticals downward from $8.70 to $7.38. They cite updated financing assumptions and recent corporate developments as key factors behind the adjustment.Anlatı Güncellemesi • Sep 25
US Launch And EMA Approval Will Expand Global Reach
Amid leadership changes and a recapitalization that add near-term execution risk despite long-term potential for mavorixafor in a substantial unmet market, analysts have lowered their price target for X4 Pharmaceuticals from $19.75 to $8.70. Analyst Commentary Leadership overhaul and new senior management introduce execution uncertainty but may improve strategic direction.Anlatı Güncellemesi • Sep 02
US Launch And EMA Approval Will Expand Global Reach
Analysts have lowered their price target for X4 Pharmaceuticals from $23.25 to $19.75, citing increased execution risks and near-term uncertainty from a leadership overhaul, tempered by optimism over recent recapitalization and the long-term potential of mavorixafor. Analyst Commentary Recent complete overhaul of the senior leadership team introduces uncertainty but also the potential for strategic renewal.Anlatı Güncellemesi • Aug 19
US Launch And EMA Approval Will Expand Global Reach
A significant reduction in X4 Pharmaceuticals’ future P/E signals lower growth expectations or improved earnings outlook, while a decreased discount rate indicates lower perceived risk, contributing to a sharp downward revision in the fair value estimate from $41.08 to $23.25. What's in the News X4 Pharmaceuticals completed a private placement, issuing 11,040,776 shares at $1.42 and 48,852,772 pre-funded warrants at $1.419, raising $85 million, led by Coastlands Capital LP and supported by top life science investors.Analiz Makalesi • Aug 12
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors
You may think that with a price-to-sales (or "P/S") ratio of 0.3x X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) is...
Yeni Anlatı • Mar 30
US Launch And EMA Approval Will Expand Global Reach
The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.Seeking Alpha • Jul 02
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Summary X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration. I discuss why I am attempting to "catch the falling knife." Read the full article on Seeking AlphaAnaliz Makalesi • Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Hissedar Getirileri
| XFOR | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -13.4% | -5.9% | -2.2% |
| 1Y | 7.4% | 34.6% | 13.1% |
Getiri vs. Endüstri: XFOR geçen yıl % 34.6 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: XFOR geçen yıl % 13.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| XFOR volatility | |
|---|---|
| XFOR Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
İstikrarlı Hisse Senedi Fiyatı: XFOR son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: XFOR 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| n/a | 45 | n/a | www.x4pharma.com |
Bir biyofarmasötik şirketi olan X4 Pharmaceuticals, Inc. bağışıklık sisteminin nadir hastalıklarının tedavisi için yeni terapötiklerin araştırılması, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Siğil, hipogamaglobulinemi, enfeksiyonlar ve miyelokateksis sendromu olan hastaların tedavisi için faz 3 klinik çalışmada olan kemokin reseptörü CXCR4'ün oral olarak küçük moleküllü seçici bir antagonisti olan XOLREMDI'yi sunmaktadır. Abbisko Therapeutics Co Ltd.
X4 Pharmaceuticals, Inc. Temel Bilgiler Özeti
| XFOR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$337.10m |
| Kazançlar(TTM) | -US$90.14m |
| Gelir(TTM) | US$15.85m |
21.9x
P/S Oranı-3.8x
F/K OranıXFOR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| XFOR gelir tablosu (TTM) | |
|---|---|
| Gelir | US$15.85m |
| Gelir Maliyeti | US$2.93m |
| Brüt Kâr | US$12.92m |
| Diğer Giderler | US$103.06m |
| Kazançlar | -US$90.14m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.91 |
| Brüt Marj | 81.51% |
| Net Kâr Marjı | -568.80% |
| Borç/Özkaynak Oranı | 49.4% |
XFOR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/11 00:09 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
X4 Pharmaceuticals, Inc. 10 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Michael Schmidt | Guggenheim Securities, LLC |